European Journal of Clinical Pharmacology

, Volume 65, Issue 9, pp 853–871

Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future

  • Kian Fan Chung
  • Gaetano Caramori
  • Ian M. Adcock
Review Article

Abstract

Inhaled corticosteroid (ICS) therapy in combination with long-acting β-adrenergic agonists represents the most important treatment for chronic airways diseases such as asthma and chronic obstructive pulmonary disease (COPD). ICS therapy forms the basis for treatment of asthma of all severities, improving asthma control, lung function and preventing exacerbations of disease. Use of ICS has also been established in the treatment of COPD, particularly symptomatic patients, who experience useful gains in quality of life, likely from an improvement in symptoms such as breathlessness and in reduction in exacerbations, and an attenuation of the yearly rate of deterioration in lung function. The addition of long-acting β-agonist (LABA) therapy with ICS increases the efficacy of ICS effects in moderate-to-severe asthma. Thus, a 800 μg daily dose of the ICS budesonide reduced severe exacerbation rates by 49% compared to a low dose of 200 μg daily, and addition of the LABA formoterol to budesonide (800 μg) led to a 63% reduction. In COPD, the effects of ICS are less prominent but there are beneficial effects on the decline in FEV1 and the rate of exacerbations. A reduction in the rate of decline in FEV1 of 16 ml/year with a 25% reduction in exacerbation rate has been reported with the salmeterol and fluticasone combination. A non-significant 17.5% reduction in all-cause mortality rate with ICS and LABA is reported. Chronic inflammation is a feature of both asthma and COPD, although there are site and characteristic differences. ICS targets this inflammation although this effect of ICS is less effective in patients with severe asthma and with COPD; however, addition of LABA may potentiate the anti-inflammatory effects of ICS. An important consideration is the presence of corticosteroid insensitivity in these patients. Currently available ICS have variably potent binding activities to specific glucocorticoid receptors, leading to inhibition of gene expression by either binding to DNA and inducing anti-inflammatory genes or by repressing the induction of pro-inflammatory mediators. Local side effects of ICS include oral candidiasis, hoarseness and dysphonia, while systemic side effects, such as easy bruising and reduction in growth velocity or bone mineral densitometry, are usually restricted to doses above maximally recommended doses. Use of LABA alone in patients with asthma increases the risk of asthma-related events including deaths, but this is less observed with the combination of ICS and LABA. Therefore, use of LABA alone is not recommended for asthma therapy. Future progress in ICS development will be characterised by the introduction of ICS with greater efficacy with a limited side-effect profile, and by longer-acting ICS that can be used in combination with once-daily LABAs. Other agents that could improve the efficacy of corticosteroids or reverse corticosteroid insensitivity may be added to ICS. ICS in combination with LABAs will continue to remain the main focus of treatment of airways diseases.

Keywords

Asthma Chronic obstructive pulmonary disease Corticosteroids Beta-adrenergic agonists Inflammation 

References

  1. 1.
    Ito K, Chung KF, Adcock IM (2006) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 117:522–543PubMedCrossRefGoogle Scholar
  2. 2.
    Weigel NL, Moore NL (2007) Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol 21:2311–2319PubMedCrossRefGoogle Scholar
  3. 3.
    Adcock IM, Barnes PJ (2008) Molecular mechanisms of corticosteroid resistance. Chest 134:394–401PubMedCrossRefGoogle Scholar
  4. 4.
    Li B, Carey M, Workman JL (2007) The role of chromatin during transcription. Cell 128:707–719PubMedCrossRefGoogle Scholar
  5. 5.
    So AY, Chaivorapol C, Bolton EC, Li H, Yamamoto KR (2007) Determinants of cell- and gene-specific transcriptional regulation by the glucocorticoid receptor. PLoS Genet 3:e94PubMedCrossRefGoogle Scholar
  6. 6.
    Xystrakis E, Kusumakar S, Boswell S, Peek E, Urry Z, Richards DF, Adikibi T, Pridgeon C, Dallman M, Loke TK et al (2006) Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J Clin Invest 116:146–155PubMedCrossRefGoogle Scholar
  7. 7.
    Ito K, Chung KF, Adcock IM (2006) Update on glucocorticoid action and resistance. J Allergy Clin Immunol 117:522–543PubMedCrossRefGoogle Scholar
  8. 8.
    De BK, Van CK, Meijer OC, Haegeman G (2008) Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol 583:290–302CrossRefGoogle Scholar
  9. 9.
    Nie M, Knox AJ, Pang L (2005) Beta2-adrenoceptor agonists, like glucocorticoids, repress eotaxin gene transcription by selective inhibition of histone H4 acetylation. J Immunol 175:478–486PubMedGoogle Scholar
  10. 10.
    Clark AR, Martins JR, Tchen CR (2008) Role of dual specificity phosphatases in biological responses to glucocorticoids. J Biol Chem 283:25765–25769PubMedCrossRefGoogle Scholar
  11. 11.
    Bhavsar P, Hew M, Khorasani N, Torrego A, Barnes PJ, Adcock I, Chung KF (2008) Relative corticosteroid insensitivity of alveolar macrophages in severe asthma compared with non-severe asthma. Thorax 63:784–790PubMedCrossRefGoogle Scholar
  12. 12.
    Meyer S, Temme C, Wahle E (2004) Messenger RNA turnover in eukaryotes: pathways and enzymes. Crit Rev Biochem Mol Biol 39:197–216PubMedCrossRefGoogle Scholar
  13. 13.
    Horvath G, Wanner A (2006) Inhaled corticosteroids: effects on the airway vasculature in bronchial asthma. Eur Respir J 27:172–187PubMedCrossRefGoogle Scholar
  14. 14.
    Norman AW, Mizwicki MT, Norman DP (2004) Steroid-hormone rapid actions, membrane receptors and a conformational ensemble model. Nat Rev Drug Discov 3:27–41PubMedCrossRefGoogle Scholar
  15. 15.
    Croxtall JD, Choudhury Q, Flower RJ (2000) Glucocorticoids act within minutes to inhibit recruitment of signalling factors to activated EGF receptors through a receptor-dependent, transcription-independent mechanism. Br J Pharmacol 130:289–298PubMedCrossRefGoogle Scholar
  16. 16.
    Jeffery PK, Godfrey RW, Adelroth E, Nelson F, Rogers A, Johansson SA (1992) Effects of treatment on airway inflammation and thickening of basement membrane reticular collagen in asthma. A quantitative light and electron microscopic study. Am Rev Respir Dis 145:890–899Google Scholar
  17. 17.
    Adelroth E, Rosenhall L, Johansson S-A, Linden M, Venge P (1990) Inflammatory cells and eosinophilic activity in asthmatics investigated by bronchoalveolar lavage: the effects of antiasthmatic treatment with budesonide or terbutaline. Am Rev Respir Dis 142:91–99PubMedGoogle Scholar
  18. 18.
    Laitinen LA, Laitinen A, Haahtele T (1992) A comparative study of the effects of an inhaled corticosteroid, budesemide, and of a β2-agonist, terbutaline, on airway inflammation in newly diagnosed asthma. J Allergy Clin Immunol 90:32–42PubMedCrossRefGoogle Scholar
  19. 19.
    Laursen LC, Taudorf E, Borgeskov S, Kobayasi T, Jensen H, Weeke B (1988) Fiberoptic bronchoscopy and bronchial mucosal biopsies in asthmatics undergoing long-term high-dose budesonide aerosol treatment. Allergy 43:284–288PubMedCrossRefGoogle Scholar
  20. 20.
    Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST (1992) The effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 145:669–674PubMedGoogle Scholar
  21. 21.
    van Rensen EL, Straathof KC, Veselic-Charvat MA, Zwinderman AH, Bel EH, Sterk PJ (1999) Effect of inhaled steroids on airway hyperresponsiveness, sputum eosinophils, and exhaled nitric oxide levels in patients with asthma. Thorax 54:403–408PubMedGoogle Scholar
  22. 22.
    Olivieri D, Chetta A, Del Donno M, Bertorelli G, Casalini A, Pesci A, Testi R, Foresi A (1997) Effect of short-term treatment with low-dose inhaled fluticasone propionate on airway inflammation and remodeling in mild asthma: a placebo-controlled study. Am J Respir Crit Care Med 155:1864–1871PubMedGoogle Scholar
  23. 23.
    Orsida BE, Li X, Hickey B, Thien F, Wilson JW, Walters EH (1999) Vascularity in asthmatic airways: relation to inhaled steroid dose. Thorax 54:289–295PubMedGoogle Scholar
  24. 24.
    Brieva JL, Danta I, Wanner A (2000) Effect of an inhaled glucocorticosteroid on airway mucosal blood flow in mild asthma. Am J Respir Crit Care Med 161:293–296PubMedGoogle Scholar
  25. 25.
    Sont JK, Willems LN, Bel EH, van Krieken JH, Vandenbroucke JP, Sterk PJ (1999) Clinical control and histopathologic outcome of asthma when using airway hyperresponsiveness as an additional guide to long-term treatment. The AMPUL Study Group. Am J Respir Crit Care Med 159:1043–1051PubMedGoogle Scholar
  26. 26.
    Gibson PG, Wong BJ, Hepperle MJ, Kline PA, Girgis-Gabardo A, Guyatt G, Dolovich J, Denburg JA, Ramsdale EH, Hargreave FE (1992) A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid. Clin Exp Allergy 22:525–532PubMedCrossRefGoogle Scholar
  27. 27.
    in’t Veen C, Smits HH, Hiemstra PS, Zwinderman AE, Sterk PJ, Bel EH (1999) Lung function and sputum characteristics of patients with severe asthma during an induced exacerbation by double-blind steroid withdrawal. Am J Respir Crit Care Med 160:93–99Google Scholar
  28. 28.
    Barnes PJ (1995) Inhaled glucocorticoids for asthma. N Engl J Med 332:868–875PubMedCrossRefGoogle Scholar
  29. 29.
    Umland SP, Schleimer RP, Johnston SL (2002) Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 15:35–50PubMedCrossRefGoogle Scholar
  30. 30.
    Schleimer RP, Bochner BS (1994) The effects of glucocorticoids on human eosinophils. J Allergy Clin Immunol 94:1202–1213PubMedCrossRefGoogle Scholar
  31. 31.
    Schleimer RP (1993) An overview of glucocorticoid anti-inflammatory actions. Eur J Clin Pharmacol 45(Suppl 1):S3–S7PubMedCrossRefGoogle Scholar
  32. 32.
    Peters SP, Naclerio RM, Schleimer RP, MacGlashan DW Jr, Pipkorn U, Lichtenstein LM (1986) The pharmacologic control of mediator release from human basophils and mast cells. Respiration 50(Suppl 2):116–122PubMedCrossRefGoogle Scholar
  33. 33.
    Djukanovic R, Wilson JW, Britten KM, Wilson SJ, Walls AF, Roche WR, Howarth PH, Holgate ST (1992) Effect of an inhaled corticosteroid on airway inflammation and symptoms in asthma. Am Rev Respir Dis 145:669–674PubMedGoogle Scholar
  34. 34.
    Majori M, Piccoli ML, Bertacco S, Cuomo A, Cantini L, Pesci A (1997) Inhaled beclomethasone dipropionate downregulates CD4 and CD8 T-lymphocyte activation in peripheral blood of patients with asthma. J Allergy Clin Immunol 100:379–382PubMedCrossRefGoogle Scholar
  35. 35.
    Wilson JW, Djukanovic R, Howarth PH, Holgate ST (1994) Inhaled beclomethasone dipropionate downregulates airway lymphocyte activation in atopic asthma. Am J Respir Crit Care Med 149:86–90PubMedGoogle Scholar
  36. 36.
    Borish L, Mascali JJ, Dishuck J, Beam WR, Martin RJ, Rosenwasser LJ (1992) Detection of alveolar macrophage-derived IL-1 beta in asthma. Inhibition with corticosteroids. J Immunol 149:3078–3082Google Scholar
  37. 37.
    Dworski R, Fitzgerald GA, Oates JA, Sheller JR (1994) Effect of oral prednisone on airway inflammatory mediators in atopic asthma. Am J Respir Crit Care Med 149:953–959PubMedGoogle Scholar
  38. 38.
    Wenzel SE, Szefler SJ, Leung DYM, Sloan SI, Rex MD, Martin RJ (1997) Bronchoscopic evaluation of severe asthma: persistent inflammation associated with high dose glucocorticoids. Amer J Respir Crit Care Med 156:737–743Google Scholar
  39. 39.
    Cox G (1995) Glucocorticoid treatment inhibits apoptosis in human neutrophils. Separation of survival and activation outcomes. J Immunol 154:4719–4725Google Scholar
  40. 40.
    Schleimer RP, Freeland HS, Peters SP, Brown KE, Derse CP (1989) An assessment of the effects of glucocorticoids on degranulation, chemotaxis, binding to vascular endothelium and formation of leukotriene B4 by purified human neutrophils. J Pharmacol Exp Ther 250:598–605PubMedGoogle Scholar
  41. 41.
    Kharitonov SA, Yates DH, Chung KF, Barnes PJ (1996) Changes in the dose of inhaled steroid affect exhaled nitric oxide levels in asthmatic patients. Eur Respir J 9:196–201PubMedCrossRefGoogle Scholar
  42. 42.
    Chung KF, Barnes PJ (1999) Cytokines in asthma. Thorax 54:825–857PubMedGoogle Scholar
  43. 43.
    Chung KF (2008) Asthma treatments: effects on the airway smooth muscle. In: Chung KF (ed) Airway smooth muscle in asthma and COPD: biology and pharmacology. John Wiley & Sons, Chichester, pp 277–302CrossRefGoogle Scholar
  44. 44.
    John M, Lim S, Seybold J, Jose P, Robichaud A, O’Connor B, Barnes PJ, Chung KF (1998) Inhaled corticosteroids increase interleukin-10 but reduce macrophage inflammatory protein-1alpha, granulocyte-macrophage colony-stimulating factor, and interferon-gamma release from alveolar macrophages in asthma. Am J Respir Crit Care Med 157:256–262PubMedGoogle Scholar
  45. 45.
    Sousa AR, Trigg CJ, Lane SJ, Hawksworth R, Nakhosteen JA, Poston RN, Lee TH (1997) Effect of inhaled glucocorticoids on IL-1 beta and IL-1 receptor antagonist (IL-1 ra) expression in asthmatic bronchial epithelium. Thorax 52:407–410PubMedCrossRefGoogle Scholar
  46. 46.
    Chung KF (1986) Role played by inflammation in the hyperreactivity of the airways in asthma. Thorax 41:657–662PubMedCrossRefGoogle Scholar
  47. 47.
    Juniper EF, Kline PA, Vanzieleghem MA, Ramsdale EH, O’Byrne PM, Hargreave FE (1990) Effect of a long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthma. Am Rev Respir Dis 142:832–836PubMedGoogle Scholar
  48. 48.
    Ward C, Pais M, Bish R, Reid D, Feltis B, Johns D, Walters EH (2002) Airway inflammation, basement membrane thickening and bronchial hyperresponsiveness in asthma. Thorax 57:309–316PubMedCrossRefGoogle Scholar
  49. 49.
    Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE (1991) Effect of inhaled budesonide on bronchial reactivity to histamine, exercise and encepnic dry air hyperventilation in patients with asthma. Thorax 46:811–816PubMedCrossRefGoogle Scholar
  50. 50.
    Barnes PJ (1990) Effect of corticosteroids on airway hyperresponsiveness. Am Rev Respir Dis 141:S70–S76PubMedGoogle Scholar
  51. 51.
    van den Berge M, Kerstjens HA, Meijer RJ, de Reus DM, Koeter GH, Kauffman HF, Postma DS (2001) Corticosteroid-induced improvement in the PC20 of adenosine monophosphate is more closely associated with reduction in airway inflammation than improvement in the PC20 of methacholine. Am J Respir Crit Care Med 164:1127–1132PubMedGoogle Scholar
  52. 52.
    Bel EH, Timmers MC, Zwinderman AH, Dijkman JH, Sterk PJ (1991) The effect of inhaled corticosteroids on the maximal degree of airway narrowing to methacholine in asthmatic subjects. Am Rev Respir Dis 143:109–113PubMedGoogle Scholar
  53. 53.
    Vathenen AS, Knox AJ, Wisniewski A, Tattersfield AE (1991) Time course of change in bronchial reactivity with an inhaled corticosteroid in asthma. Am Rev Respir Dis 143:1317–1321PubMedGoogle Scholar
  54. 54.
    Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Selroos O, Sovijarvi A et al (1994) Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. N Engl J Med 331:700–705PubMedCrossRefGoogle Scholar
  55. 55.
    Juniper EF, Kline PA, Vanzieleghem MA, Hargreave FE (1991) Reduction of budesonide after a year of increased use: a randomized controlled trial to evaluate whether improvements in airway responsiveness and clinical asthma are maintained. J Allergy Clin Immunol 87:483–489PubMedCrossRefGoogle Scholar
  56. 56.
    Barnes PJ (2000) Chronic obstructive pulmonary disease. N Engl J Med 343:269–280PubMedCrossRefGoogle Scholar
  57. 57.
    Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, Van Weel C et al (2007) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 176:532–555PubMedCrossRefGoogle Scholar
  58. 58.
    Hogg JC, Chu F, Utokaparch S, Woods R, Elliott WM, Buzatu L, Cherniack RM, Rogers RM, Sciurba FC, Coxson HO et al (2004) The nature of small-airway obstruction in chronic obstructive pulmonary disease. N Engl J Med 350:2645–2653PubMedCrossRefGoogle Scholar
  59. 59.
    Saetta M, Turato G, Maestrelli P, Mapp CE, Fabbri LM (2001) Cellular and structural bases of chronic obstructive pulmonary disease. Am. J Respir Crit Care Med 163:1304–1309PubMedGoogle Scholar
  60. 60.
    Chung KF, Adcock IM (2008) Multi-faceted mechanism in COPD: inflammation, immunity and tissue repair and destruction. Eur Respir J 31:1334–1356PubMedCrossRefGoogle Scholar
  61. 61.
    Gan WQ, Man P, Sin DD (2005) Effects of inhaled corticosteroids on sputum cell counts in stable chronic obstructive pulmonary disease: a systematic review and a meta-analysis. BMC Pulm Med 5:3–3PubMedCrossRefGoogle Scholar
  62. 62.
    Boorsma M, Lutter R, van de Pol MA, Out TA, Jansen HM, Jonkers RE (2008) Long-term effects of budesonide on inflammatory status in COPD. COPD 5:97–104PubMedGoogle Scholar
  63. 63.
    Chanez P, Vignola AM, O’Shaugnessy T, Enander I, Li D, Jeffery PK, Bousquet J (1997) Corticosteroid reversibility in COPD is related to features of asthma. Am J Respir Crit Care Med 155:1529–1534PubMedGoogle Scholar
  64. 64.
    Brightling CE, Monteiro W, Ward R, Parker D, Morgan MD, Wardlaw AJ, Pavord ID (2000) Sputum eosinophilia and short-term response to prednisolone in chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 356:1480–1485PubMedCrossRefGoogle Scholar
  65. 65.
    Hattotuwa KL, Gizycki MJ, Ansari TW, Jeffery PK, Barnes NC (2002) The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebo-controlled biopsy study. Am J Respir Crit Care Med 165:1592–1596PubMedCrossRefGoogle Scholar
  66. 66.
    Gizycki MJ, Hattotuwa KL, Barnes N, Jeffery PK (2002) Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissue. Thorax 57:799–803PubMedCrossRefGoogle Scholar
  67. 67.
    Barnes NC, Qiu YS, Pavord ID, Parker D, Davis PA, Zhu J, Johnson M, Thomson NC, Jeffery PK (2006) Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am J Respir Crit Care Med 173:736–743PubMedCrossRefGoogle Scholar
  68. 68.
    Sin DD, Man SF, Marciniuk DD, Ford G, Fitzgerald M, Wong E, York E, Mainra RR, Ramesh W, Melenka LS et al (2008) The effects of fluticasone with or without salmeterol on systemic biomarkers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 177:1207–1214PubMedCrossRefGoogle Scholar
  69. 69.
    Man SF, Sin DD (2005) Effects of corticosteroids on systemic inflammation in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2:78–82PubMedCrossRefGoogle Scholar
  70. 70.
    Adcock IM, Maneechotesuwan K, Usmani O (2002) Molecular interactions between glucocorticoids and long-acting beta2-agonists. J Allergy Clin Immunol 110:S261–S268PubMedCrossRefGoogle Scholar
  71. 71.
    Usmani OS, Ito K, Maneechotesuwan K, Ito M, Johnson M, Barnes PJ, Adcock IM (2005) Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am J Respir Crit Care Med 172:704–712PubMedCrossRefGoogle Scholar
  72. 72.
    Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, Anderson G, Tamm M, Black JL (2002) Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 360:1293–1299PubMedCrossRefGoogle Scholar
  73. 73.
    Chung KF, Adcock IM (2004) Combination therapy of long-acting beta2-adrenoceptor agonists and corticosteroids for asthma. Treat Respir Med 3:279–289PubMedCrossRefGoogle Scholar
  74. 74.
    Sin DD, Man SF (2006) Corticosteroids and adrenoceptor agonists: the compliments for combination therapy in chronic airways diseases. Eur J Pharmacol 533:28–35PubMedCrossRefGoogle Scholar
  75. 75.
    Moore WC, Bleecker ER, Curran-Everett D, Erzurum SC, Ameredes BT, Bacharier L, Calhoun WJ, Castro M, Chung KF, Clark MP et al (2007) Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute’s Severe Asthma Research Program. J Allergy Clin Immunol 119:405–413PubMedCrossRefGoogle Scholar
  76. 76.
    Bumbacea D, Campbell D, Nguyen L, Carr D, Barnes PJ, Robinson D, Chung KF (2004) Parameters associated with persistent airflow obstruction in chronic severe asthma. Eur Respir J 24:122–128PubMedCrossRefGoogle Scholar
  77. 77.
    Robinson DS, Campbell DA, Durham SR, Pfeffer J, Barnes PJ, Chung KF (2003) Systematic assessment of difficult-to-treat asthma. Eur Respir J 22:478–483PubMedCrossRefGoogle Scholar
  78. 78.
    Jatakanon A, Uasuf C, Maziak W, Lim S, Chung KF, Barnes PJ (1999) Neutrophilic inflammation in severe persistent asthma. Am J Respir Crit Care Med 160:1532–1539PubMedGoogle Scholar
  79. 79.
    Wenzel SE, Schwartz LB, Langmack EL, Halliday JL, Trudeau JB, Gibbs RL, Chu HW (1999) Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 160:1001–1008PubMedGoogle Scholar
  80. 80.
    Benayoun L, Druilhe A, Dombret MC, Aubier M, Pretolani M (2003) Airway structural alterations selectively associated with severe asthma. Am J Respir Crit Care Med 167:1360–1368PubMedCrossRefGoogle Scholar
  81. 81.
    Bourdin A, Neveu D, Vachier I, Paganin F, Godard P, Chanez P (2007) Specificity of basement membrane thickening in severe asthma. J Allergy Clin Immunol 119:1367–1374PubMedCrossRefGoogle Scholar
  82. 82.
    Cohen L, Xueping E, Tarsi J, Ramkumar T, Horiuchi TK, Cochran R, DeMartino S, Schechtman KB, Hussain I, Holtzman MJ et al (2007) Epithelial cell proliferation contributes to airway remodeling in severe asthma. Am J Respir Crit Care Med 176:138–145PubMedCrossRefGoogle Scholar
  83. 83.
    Hew M, Bhavsar P, Torrego A, Meah S, Khorasani N, Barnes PJ, Adcock I, Fan CK (2006) Relative corticosteroid insensitivity of peripheral blood mononuclear cells in severe asthma. Am J Respir Crit Care Med 174:134–141PubMedCrossRefGoogle Scholar
  84. 84.
    Culpitt SV, Rogers DF, Shah P, De Matos C, Russell REK, Donnelly LE, Barnes PJ (2003) Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 167:24–31PubMedCrossRefGoogle Scholar
  85. 85.
    Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, Barczyk A, Hayashi S, Adcock IM, Hogg JC et al (2005) Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med 352:1967–1976PubMedCrossRefGoogle Scholar
  86. 86.
    Marban C, Suzanne S, Dequiedt F, de Walque S, Redel L, Van Lint C, Aunis D, Rohr O (2007) Recruitment of chromatin-modifying enzymes by CTIP2 promotes HIV-1 transcriptional silencing. EMBO J 26:412–423PubMedCrossRefGoogle Scholar
  87. 87.
    Szulakowski P, Crowther AJ, Jimenez LA, Donaldson K, Mayer R, Leonard TB, MacNee W, Drost EM (2006) The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 174:41–50PubMedCrossRefGoogle Scholar
  88. 88.
    Ito K, Lim S, Caramori G, Cosio B, Chung KF, Adcock IM, Barnes PJ (2002) A molecular mechanism of action of theophylline: induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Natl Acad Sci USA 99:8921–8926PubMedCrossRefGoogle Scholar
  89. 89.
    Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 203:7–13PubMedCrossRefGoogle Scholar
  90. 90.
    Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, Hamid Q (1995) Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 181:33–40PubMedCrossRefGoogle Scholar
  91. 91.
    Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM (2002) p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109:649–657PubMedCrossRefGoogle Scholar
  92. 92.
    Webster JC, Oakley RH, Jewell CM, Cidlowski JA (2001) Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative beta isoform: a mechanism for the generation of glucocorticoid resistance. Proc Natl Acad Sci USA 98:6865–6870PubMedCrossRefGoogle Scholar
  93. 93.
    Goleva E, Li LB, Eves PT, Strand MJ, Martin RJ, Leung DY (2006) Increased glucocorticoid receptor beta alters steroid response in glucocorticoid-insensitive asthma. Am J Respir Crit Care Med 173:607–616PubMedCrossRefGoogle Scholar
  94. 94.
    Lane SJ, Adcock IM, Richards D, Hawrylowicz C, Barnes PJ, Lee TH (1998) Corticosteroid-resistant bronchial asthma is associated with increased c-fos expression in monocytes and T lymphocytes. J Clin Invest 102:2156–2164PubMedCrossRefGoogle Scholar
  95. 95.
    Barnes PJ, Ito K, Adcock IM (2004) Corticosteroid resistance in chronic obstructive pulmonary disease: inactivation of histone deacetylase. Lancet 363:731–733PubMedCrossRefGoogle Scholar
  96. 96.
    Ito K, Yamamura S, Essilfie-Quaye S, Cosio B, Ito M, Barnes PJ, Adcock IM (2006) Histone deacetylase 2-mediated deacetylation of the glucocorticoid receptor enables NF-kappaB suppression. J Exp Med 203:7–13PubMedCrossRefGoogle Scholar
  97. 97.
    Hawrylowicz CM (2005) Regulatory T cells and IL-10 in allergic inflammation. J Exp Med 202:1459–1463PubMedCrossRefGoogle Scholar
  98. 98.
    Biggadike K, Uings I, Farrow SN (2004) Designing corticosteroid drugs for pulmonary selectivity. Proc Am Thorac Soc 1:352–355PubMedCrossRefGoogle Scholar
  99. 99.
    Johnson M (1996) Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol 97:169–176PubMedCrossRefGoogle Scholar
  100. 100.
    Winkler J, Hochhaus G, Derendorf H (2004) How the lung handles drugs: pharmacokinetics and pharmacodynamics of inhaled corticosteroids. Proc Am Thorac Soc 1:356–363PubMedCrossRefGoogle Scholar
  101. 101.
    Valotis A, Hogger P (2007) Human receptor kinetics and lung tissue retention of the enhanced-affinity glucocorticoid fluticasone furoate. Respir Res 8:54PubMedCrossRefGoogle Scholar
  102. 102.
    Harrison TW, Wisniewski A, Honour J, Tattersfield AE (2001) Comparison of the systemic effects of fluticasone propionate and budesonide given by dry powder inhaler in healthy and asthmatic subjects. Thorax 56:186–191PubMedCrossRefGoogle Scholar
  103. 103.
    Harrison TW, Tattersfield AE (2003) Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 58:258–260PubMedCrossRefGoogle Scholar
  104. 104.
    Harrison TW (2001) Systemic availability of inhaled budesonide and fluticasone propionate: healthy versus asthmatic lungs. BioDrugs 15:405–411PubMedCrossRefGoogle Scholar
  105. 105.
    Adams NP, Jones PW (2006) The dose-response characteristics of inhaled corticosteroids when used to treat asthma: an overview of Cochrane systematic reviews. Respir Med 100:1297–1306PubMedCrossRefGoogle Scholar
  106. 106.
    Adams NP, Bestall JC, Jones P, Lasserson TJ, Griffiths B, Cates CJ (2008) Fluticasone at different doses for chronic asthma in adults and children. Cochrane Database Syst Rev CD003534Google Scholar
  107. 107.
    Mahler DA, Wire P, Horstman D, Chang CN, Yates J, Fischer T, Shah T (2002) Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 166:1084–1091PubMedCrossRefGoogle Scholar
  108. 108.
    Hanania NA, Darken P, Horstman D, Reisner C, Lee B, Davis S, Shah T (2003) The efficacy and safety of fluticasone propionate (250 microg)/salmeterol (50 microg) combined in the Diskus inhaler for the treatment of COPD. Chest 124:834–843PubMedCrossRefGoogle Scholar
  109. 109.
    Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C (2003) Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 361:449–456PubMedCrossRefGoogle Scholar
  110. 110.
    Salmeron S, Guerin JC, Godard P, Renon D, Henry-Amar M, Duroux P, Taytard A (1989) High doses of inhaled corticosteroids in unstable chronic asthma. A multicenter, double-blind, placebo-controlled study. Am Rev Respir Dis 140:167–171PubMedGoogle Scholar
  111. 111.
    Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, Nikander K, Persson T, Reinikainen K, Selroos O et al (1991) Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma [see comments]. N Engl J Med 325:388–392PubMedGoogle Scholar
  112. 112.
    Pauwels RA, Pedersen S, Busse WW, Tan WC, Chen YZ, Ohlsson SV, Ullman A, Lamm CJ, O’Byrne PM (2003) Early intervention with budesonide in mild persistent asthma: a randomised, double-blind trial. Lancet 361:1071–1076PubMedCrossRefGoogle Scholar
  113. 113.
    (2000) Long-term effects of budesonide or nedocromil in children with asthma. The Childhood Asthma Management Program Research Group. N Engl J Med 343:1054–1063Google Scholar
  114. 114.
    O’Byrne PM, Barnes PJ, Rodriguez-Roisin R, Runnerstrom E, Sandstrom T, Svensson K, Tattersfield A (2001) Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial. Am J Respir Crit Care Med 164:1392–1397PubMedGoogle Scholar
  115. 115.
    Israel E, Chervinsky PS, Friedman B, van Bavel J, Skalky CS, Ghannam AF, Bird SR, Edelman JM (2002) Effects of montelukast and beclomethasone on airway function and asthma control. J Allergy Clin Immunol 110:847–854PubMedCrossRefGoogle Scholar
  116. 116.
    Baumgartner RA, Martinez G, Edelman JM, Rodriguez Gomez GG, Bernstein M, Bird S, Angner R, Polis A, Dass SB, Lu S et al (2003) Distribution of therapeutic response in asthma control between oral montelukast and inhaled beclomethasone. Eur Respir J 21:123–128PubMedCrossRefGoogle Scholar
  117. 117.
    Papi A, Canonica GW, Maestrelli P, Paggiaro P, Olivieri D, Pozzi E, Crimi N, Vignola AM, Morelli P, Nicolini G et al (2007) Rescue use of beclomethasone and albuterol in a single inhaler for mild asthma. N Engl J Med 356:2040–2052PubMedCrossRefGoogle Scholar
  118. 118.
    Boushey HA, Sorkness CA, King TS, Sullivan SD, Fahy JV, Lazarus SC, Chinchilli VM, Craig TJ, Dimango EA, Deykin A et al (2005) Daily versus as-needed corticosteroids for mild persistent asthma. N Engl J Med 352:1519–1528PubMedCrossRefGoogle Scholar
  119. 119.
    Martin RJ, Szefler SJ, King TS, Kraft M, Boushey HA, Chinchilli VM, Craig TJ, Dimango EA, Deykin A, Fahy JV et al (2007) The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial. J Allergy Clin Immunol 119:73–80PubMedCrossRefGoogle Scholar
  120. 120.
    Lazarus SC, Chinchilli VM, Rollings NJ, Boushey HA, Cherniack R, Craig TJ, Deykin A, DiMango E, Fish JE, Ford JG et al (2007) Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma. Am J Respir Crit Care Med 175:783–790PubMedCrossRefGoogle Scholar
  121. 121.
    Chalmers GW, MacLeod KJ, Little SA, Thomson LJ, McSharry CP, Thomson NC (2002) Influence of cigarette smoking on inhaled corticosteroid treatment in mild asthma. Thorax 57:226–230PubMedCrossRefGoogle Scholar
  122. 122.
    Duong M, Gauvreau G, Watson R, Obminski G, Strinich T, Evans M, Howie K, Killian K, O’Byrne PM (2007) The effects of inhaled budesonide and formoterol in combination and alone when given directly after allergen challenge. J Allergy Clin Immunol 119:322–327PubMedCrossRefGoogle Scholar
  123. 123.
    Sin DD, Man J, Sharpe H, Gan WQ, Man SF (2004) Pharmacological management to reduce exacerbations in adults with asthma: a systematic review and meta-analysis. JAMA 292:367–376PubMedCrossRefGoogle Scholar
  124. 124.
    Greenstone IR, Ni Chroinin MN, Masse V, Danish A, Magdalinos H, Zhang X, Ducharme FM (2005) Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev CD005533Google Scholar
  125. 125.
    O’Byrne PM, Bisgaard H, Godard PP, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman ED (2005) Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma. Am J Respir Crit Care Med 171:129–136PubMedCrossRefGoogle Scholar
  126. 126.
    Woolcock A, Lundback B, Ringdal N, Jacques LA (1996) Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am J Respir Crit Care Med 153:1481–1488PubMedGoogle Scholar
  127. 127.
    Zetterstrom O, Buhl R, Mellem H, Perpina M, Hedman J, O’Neill S, Ekstrom T (2001) Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone. Eur Respir J 18:262–268PubMedCrossRefGoogle Scholar
  128. 128.
    Bateman ED, Boushey HA, Bousquet J, Busse WW, Clark TJ, Pauwels RA, Pedersen SE (2004) Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study. Am J Respir Crit Care Med 170:836–844PubMedCrossRefGoogle Scholar
  129. 129.
    Pauwels RA, Lofdahl C, Postma D, Tattersfield A, O’Byrne P, Barnes PJ, Ullman A (1997) Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337:1405–1411PubMedCrossRefGoogle Scholar
  130. 130.
    Overbeek SE, Mulder PG, Baelemans SM, Hoogsteden HC, Prins JB (2005) Formoterol added to low-dose budesonide has no additional antiinflammatory effect in asthmatic patients. Chest 128:1121–1127PubMedCrossRefGoogle Scholar
  131. 131.
    Koopmans JG, Lutter R, Jansen HM, van der Zee JS (2006) Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma. Thorax 61:306–312PubMedCrossRefGoogle Scholar
  132. 132.
    Koopmans JG, Lutter R, Jansen HM, van der Zee JS (2005) Adding salmeterol to an inhaled corticosteroid reduces allergen-induced serum IL-5 and peripheral blood eosinophils. J Allergy Clin Immunol 116:1007–1013PubMedCrossRefGoogle Scholar
  133. 133.
    Rabe KF, Atienza T, Magyar P, Larsson P, Jorup C, Lalloo UG (2006) Effect of budesonide in combination with formoterol for reliever therapy in asthma exacerbations: a randomised controlled, double-blind study. Lancet 368:744–753PubMedCrossRefGoogle Scholar
  134. 134.
    Bateman ED, Jacques L, Goldfrad C, Atienza T, Mihaescu T, Duggan M (2006) Asthma control can be maintained when fluticasone propionate/salmeterol in a single inhaler is stepped down. J Allergy Clin Immunol 117:563–570PubMedCrossRefGoogle Scholar
  135. 135.
    Lotvall J, Langley S, Woodcock A (2006) Inhaled steroid/long-acting beta 2 agonist combination products provide 24 hours improvement in lung function in adult asthmatic patients. Respir Res 7:110PubMedCrossRefGoogle Scholar
  136. 136.
    Tarsin WY, Pearson SB, Assi KH, Chrystyn H (2006) Emitted dose estimates from Seretide Diskus and Symbicort Turbuhaler following inhalation by severe asthmatics. Int J Pharm 316:131–137PubMedCrossRefGoogle Scholar
  137. 137.
    Vogelmeier C, D’Urzo A, Pauwels R, Merino JM, Jaspal M, Boutet S, Naya I, Price D (2005) Budesonide/formoterol maintenance and reliever therapy: an effective asthma treatment option? Eur Respir J 26:819–828PubMedCrossRefGoogle Scholar
  138. 138.
    Fitzgerald JM, Boulet LP, Follows RM (2005) The CONCEPT trial: a 1-year, multicenter, randomized, double-blind, double-dummy comparison of a stable dosing regimen of salmeterol/fluticasone propionate with an adjustable maintenance dosing regimen of formoterol/budesonide in adults with persistent asthma. Clin Ther 27:393–406PubMedCrossRefGoogle Scholar
  139. 139.
    Papi A, Paggiaro PL, Nicolini G, Vignola AM, Fabbri LM (2007) Beclomethasone/formoterol versus budesonide/formoterol combination therapy in asthma. Eur Respir J 29:682–689PubMedCrossRefGoogle Scholar
  140. 140.
    Bousquet J, Boulet LP, Peters MJ, Magnussen H, Quiralte J, Martinez-Aguilar NE, Carlsheimer A (2007) Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med 101:2437–2446PubMedCrossRefGoogle Scholar
  141. 141.
    Huchon G, Magnussen H, Chuchalin A, Dymek L, Gonod FB, Bousquet J (2009) Lung function and asthma control with beclomethasone and formoterol in a single inhaler. Respir Med 103:41–49PubMedCrossRefGoogle Scholar
  142. 142.
    Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK (2000) Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 320:1297–1303CrossRefGoogle Scholar
  143. 143.
    Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS (2001) Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 345:941–947PubMedCrossRefGoogle Scholar
  144. 144.
    Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS (2001) Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 163:1256–1276PubMedGoogle Scholar
  145. 145.
    Culpitt SV, Maziak W, Loukidis S, Nightingale JA, Matthews JL, Barnes PJ (1999) Effect of high dose inhaled steroid on cells, cytokines, and proteases in induced sputum in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 160:1635–1639PubMedGoogle Scholar
  146. 146.
    Keatings VM, Jatakanon A, Worsdell YM, Barnes PJ (1997) Effects of inhaled and oral glucocorticoids on inflammatory indices in asthma and COPD. Am J Respir Crit Care Med 155:542–548PubMedGoogle Scholar
  147. 147.
    Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K (1999) Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 353:1819–1823PubMedCrossRefGoogle Scholar
  148. 148.
    Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV (1999) Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 340:1948–1953PubMedCrossRefGoogle Scholar
  149. 149.
    Lung Health Study Research Group (2000) Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 343:1902–1909CrossRefGoogle Scholar
  150. 150.
    Sutherland ER (2003) Inhaled corticosteroids in chronic obstructive pulmonary disease. Ann Intern Med 139:864–865PubMedGoogle Scholar
  151. 151.
    Highland KB, Strange C, Heffner JE (2003) Long-term effects of inhaled corticosteroids on FEV1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 138:969–973PubMedGoogle Scholar
  152. 152.
    Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins CR, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM (2008) Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 178:332–338PubMedCrossRefGoogle Scholar
  153. 153.
    Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H (2003) Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 21:74–81PubMedCrossRefGoogle Scholar
  154. 154.
    Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J (2007) Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 356:775–789PubMedCrossRefGoogle Scholar
  155. 155.
    van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C (2002) Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 166:1358–1363PubMedCrossRefGoogle Scholar
  156. 156.
    Paggiaro PL, Dahle R, Bakran I, Frith L, Hollingworth K, Efthimiou J (1998) Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet 351:773–780PubMedCrossRefGoogle Scholar
  157. 157.
    Calverley PM, Rennard S, Nelson HS, Karpel JP, Abbate EH, Stryszak P, Staudinger H (2008) One-year treatment with mometasone furoate in chronic obstructive pulmonary disease. Respir Res 9:73PubMedCrossRefGoogle Scholar
  158. 158.
    Wilt TJ, Niewoehner D, MacDonald R, Kane RL (2007) Management of stable chronic obstructive pulmonary disease: a systematic review for a clinical practice guideline. Ann Intern Med 147:639–653PubMedGoogle Scholar
  159. 159.
    Calverley PM, Sanchez-Toril F, McIvor A, Teichmann P, Bredenbroeker D, Fabbri LM (2007) Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 176:154–161PubMedCrossRefGoogle Scholar
  160. 160.
    Sin DD, McAlister FA, Man SF, Anthonisen NR (2003) Contemporary management of chronic obstructive pulmonary disease: scientific review. JAMA 290:2301–2312PubMedCrossRefGoogle Scholar
  161. 161.
    van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C (2002) Effect of discontinuation of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 166:1358–1363PubMedCrossRefGoogle Scholar
  162. 162.
    Jones PW, Willits LR, Burge PS, Calverley PM (2003) Disease severity and the effect of fluticasone propionate on chronic obstructive pulmonary disease exacerbations. Eur Respir J 21:68–73PubMedCrossRefGoogle Scholar
  163. 163.
    Wouters EF, Postma DS, Fokkens B, Hop WC, Prins J, Kuipers AF, Pasma HR, Hensing CA, Creutzberg EC (2005) Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax 60:480–487PubMedCrossRefGoogle Scholar
  164. 164.
    O’Brien A, Russo-Magno P, Karki A, Hiranniramol S, Hardin M, Kaszuba M, Sherman C, Rounds S (2001) Effects of withdrawal of inhaled steroids in men with severe irreversible airflow obstruction. Am J Respir Crit Care Med 164:365–371PubMedGoogle Scholar
  165. 165.
    Sin DD, Tu JV (2001) Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 164:580–584PubMedGoogle Scholar
  166. 166.
    Soriano JB, Kiri VA, Pride NB, Vestbo J (2003) Inhaled corticosteroids with/without long-acting beta-agonists reduce the risk of rehospitalization and death in COPD patients. Am J Respir Med 2:67–74PubMedGoogle Scholar
  167. 167.
    Soriano JB, Vestbo J, Pride NB, Kiri V, Maden C, Maier WC (2002) Survival in COPD patients after regular use of fluticasone propionate and salmeterol in general practice. Eur Respir J 20:819–825PubMedCrossRefGoogle Scholar
  168. 168.
    Suissa S (2004) Inhaled steroids and mortality in COPD: bias from unaccounted immortal time. Eur Respir J 23:391–395PubMedCrossRefGoogle Scholar
  169. 169.
    Sin DD, Man SF (2007) Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can J Physiol Pharmacol 85:141–147PubMedCrossRefGoogle Scholar
  170. 170.
    Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H (2003) Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 22:912–919PubMedCrossRefGoogle Scholar
  171. 171.
    Jones PW (1991) Measurement of quality of life in chronic obstructive lung disease. Eur Resp Rev 1:445–453Google Scholar
  172. 172.
    Fitzgerald JM, Becker A, Sears MR, Mink S, Chung K, Lee J (2004) Doubling the dose of budesonide versus maintenance treatment in asthma exacerbations. Thorax 59:550–556PubMedCrossRefGoogle Scholar
  173. 173.
    Harrison TW, Oborne J, Newton S, Tattersfield AE (2004) Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363:271–275PubMedCrossRefGoogle Scholar
  174. 174.
    Rice-McDonald G, Bowler S, Staines G, Mitchell C (2005) Doubling daily inhaled corticosteroid dose is ineffective in mild to moderately severe attacks of asthma in adults. Intern Med J 35:693–698PubMedCrossRefGoogle Scholar
  175. 175.
    Gibson PG, Saltos N, Fakes K (2001) Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 163:32–36PubMedGoogle Scholar
  176. 176.
    Rodrigo G, Rodrigo C (1998) Inhaled flunisolide for acute severe asthma. Am J Respir Crit Care Med 157:698–703PubMedGoogle Scholar
  177. 177.
    Rodrigo GJ, Rodrigo C (2000) Rapid-onset asthma attack: a prospective cohort study about characteristics and response to emergency department treatment. Chest 118:1547–1552PubMedCrossRefGoogle Scholar
  178. 178.
    Edmonds ML, Camargo CA Jr, Pollack CV Jr, Rowe BH (2003) Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev CD002308Google Scholar
  179. 179.
    Di Franco A, Bacci E, Bartoli ML, Cianchetti S, Dente FL, Taccola M, Vagaggini B, Zingoni M, Paggiaro PL (2006) Inhaled fluticasone propionate is effective as well as oral prednisone in reducing sputum eosinophilia during exacerbations of asthma which do not require hospitalization. Pulm Pharmacol Ther 19:353–360PubMedCrossRefGoogle Scholar
  180. 180.
    Levy ML, Stevenson C, Maslen T (1996) Comparison of short courses of oral prednisolone and fluticasone propionate in the treatment of adults with acute exacerbations of asthma in primary care. Thorax 51:1087–1092PubMedCrossRefGoogle Scholar
  181. 181.
    Foresi A, Morelli MC, Catena E (2000) Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control. On behalf of the Italian Study Group. Chest 117:440–446PubMedCrossRefGoogle Scholar
  182. 182.
    Reddel HK, Barnes DJ (2006) Pharmacological strategies for self-management of asthma exacerbations. Eur Respir J 28:182–199PubMedCrossRefGoogle Scholar
  183. 183.
    Maltais F, Ostinelli J, Bourbeau J, Tonnel AB, Jacquemet N, Haddon J, Rouleau M, Boukhana M, Martinot JB, Duroux P (2002) Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med 165:698–703PubMedGoogle Scholar
  184. 184.
    Donnelly R, Williams KM, Baker AB, Badcock CA, Day RO, Seale JP (1997) Effects of budesonide and fluticasone on 24-hour plasma cortisol. A dose-response study. Am J Respir Crit Care Med 156:1746–1751PubMedGoogle Scholar
  185. 185.
    Clark DJ, Grove A, Cargill RI, Lipworth BJ (1996) Comparative adrenal suppression with inhaled budesonide and fluticasone propionate in adult asthmatic patients. Thorax 51:262–266PubMedCrossRefGoogle Scholar
  186. 186.
    Todd GR (2003) Adrenal crisis due to inhaled steroids is underestimated. Arch Dis Child 88:554–555PubMedCrossRefGoogle Scholar
  187. 187.
    Todd GR, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D (2002) Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Arch Dis Child 87:457–461PubMedCrossRefGoogle Scholar
  188. 188.
    Cumming RG, Mitchell P, Leeder SR (1997) Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 337:8–14PubMedCrossRefGoogle Scholar
  189. 189.
    Garbe E, LeLorier J, Boivin JF, Suissa S (1997) Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA 277:722–727PubMedCrossRefGoogle Scholar
  190. 190.
    Wong CA, Walsh LJ, Smith CJ, Wisniewski AF, Lewis SA, Hubbard R, Cawte S, Green DJ, Pringle M, Tattersfield AE (2000) Inhaled corticosteroid use and bone-mineral density in patients with asthma. Lancet 355:1399–1403PubMedCrossRefGoogle Scholar
  191. 191.
    Pedersen S (2006) Clinical safety of inhaled corticosteroids for asthma in children: an update of long-term trials. Drug Saf 29:599–612PubMedCrossRefGoogle Scholar
  192. 192.
    Tattersfield AE, Town GI, Johnell O, Picado C, Aubier M, Braillon P, Karlstrom R (2001) Bone mineral density in subjects with mild asthma randomised to treatment with inhaled corticosteroids or non-corticosteroid treatment for two years. Thorax 56:272–278PubMedCrossRefGoogle Scholar
  193. 193.
    Elmstahl S, Ekstrom H, Galvard H, Johnell O, Gerhardsson de Verdier M, Norjavaara E (2003) Is there an association between inhaled corticosteroids and bone density in postmenopausal women? J Allergy Clin Immunol 111:91–96PubMedCrossRefGoogle Scholar
  194. 194.
    Kelly HW, Van Natta ML, Covar RA, Tonascia J, Green RP, Strunk RC (2008) Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Ped 122:e53–e61CrossRefGoogle Scholar
  195. 195.
    van Staa TP, Leufkens HG, Cooper C (2001) Use of inhaled corticosteroids and risk of fractures. J Bone Miner Res 16:581–588PubMedCrossRefGoogle Scholar
  196. 196.
    Suissa S, Baltzan M, Kremer R, Ernst P (2004) Inhaled and nasal corticosteroid use and the risk of fracture. Am J Respir Crit Care Med 169:83–88PubMedCrossRefGoogle Scholar
  197. 197.
    Lee TA, Weiss KB, Sullivan SD (2004) Cost-effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease. Am J Med 117:618–619PubMedCrossRefGoogle Scholar
  198. 198.
    Etminan M, Sadatsafavi M, Ganjizadeh ZS, Takkouche B, Fitzgerald JM (2008) Inhaled corticosteroids and the risk of fractures in older adults: a systematic review and meta-analysis. Drug Saf 31:409–414PubMedCrossRefGoogle Scholar
  199. 199.
    Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM (2006) The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 129:15–26PubMedCrossRefGoogle Scholar
  200. 200.
    Kramer JM (2009) Balancing the benefits and risks of inhaled long-acting beta-agonists-the influence of values. N Engl J Med 360:1592–1595PubMedCrossRefGoogle Scholar
  201. 201.
    Paul-Clark MJ, Roviezzo F, Flower RJ, Cirino G, Soldato PD, Adcock IM, Perretti M (2003) Glucocorticoid receptor nitration leads to enhanced anti-inflammatory effects of novel steroid ligands. J Immunol 171:3245–3252PubMedGoogle Scholar
  202. 202.
    Nevin BJ, Broadley KJ (2004) Comparative effects of inhaled budesonide and the NO-donating budesonide derivative, NCX 1020, against leukocyte influx and airway hyperreactivity following lipopolysaccharide challenge. Pulm Pharmacol Ther 17:219–232PubMedCrossRefGoogle Scholar
  203. 203.
    Adcock IM, Caramori G, Chung KF (2008) New targets for drug development in asthma. Lancet 372:1073–1087PubMedCrossRefGoogle Scholar
  204. 204.
    Derendorf H (2007) Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 47:782–789PubMedCrossRefGoogle Scholar
  205. 205.
    Schacke H, Berger M, Rehwinkel H, Asadullah K (2007) Selective glucocorticoid receptor agonists (SEGRAs): novel ligands with an improved therapeutic index. Mol Cell Endocrinol 275:109–117PubMedCrossRefGoogle Scholar
  206. 206.
    Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, Rehwinkel H, Hennekes H, Asadullah K (2004) Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci USA 101:227–232PubMedCrossRefGoogle Scholar
  207. 207.
    Schacke H, Docke WD, Asadullah K (2002) Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther 96:23–43PubMedCrossRefGoogle Scholar
  208. 208.
    Miner JN, Ardecky B, Benbatoul K, Griffiths K, Larson CJ, Mais DE, Marschke K, Rosen J, Vajda E, Zhi L et al (2007) Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile. Proc Natl Acad Sci USA 104:19244–19249PubMedCrossRefGoogle Scholar
  209. 209.
    Ogawa S, Lozach J, Benner C, Pascual G, Tangirala RK, Westin S, Hoffmann A, Subramaniam S, David M, Rosenfeld MG et al (2005) Molecular determinants of crosstalk between nuclear receptors and toll-like receptors. Cell 122:707–721PubMedCrossRefGoogle Scholar
  210. 210.
    Farrow SN (2008) Nuclear receptors: doubling up in the lung. Curr Opin Pharmacol 8:275–279PubMedCrossRefGoogle Scholar
  211. 211.
    Renda T, Baraldo S, Pelaia G, Bazzan E, Turato G, Papi A, Maestrelli P, Maselli R, Vatrella A, Fabbri LM et al (2008) Increased activation of p38 MAPK in COPD. Eur Respir J 31:62–69PubMedCrossRefGoogle Scholar
  212. 212.
    Ito K, Caramori G, Adcock IM (2007) Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease. J Pharmacol Exp Ther 321:1–8PubMedCrossRefGoogle Scholar
  213. 213.
    Adcock IM, Caramori G, Chung KF (2008) New targets for drug development in asthma. Lancet 372:1073–1087PubMedCrossRefGoogle Scholar
  214. 214.
    Marwick JA, Stevenson CS, Barnes PJ, Ito K, Adcock IM, Kirkham PA (2008) Cigarette smoke reduces steroid sensitivity by reducing glucocorticoid receptor (GR) and GR co-repressor expression. Proc Am Thorac Soc 5:A333Google Scholar
  215. 215.
    Irusen E, Matthews JG, Takahashi A, Barnes PJ, Chung KF, Adcock IM (2002) p38 Mitogen-activated protein kinase-induced glucocorticoid receptor phosphorylation reduces its activity: role in steroid-insensitive asthma. J Allergy Clin Immunol 109:649–657PubMedCrossRefGoogle Scholar
  216. 216.
    Kent L, Smyth L, Plumb J, Clayton C, Fox S, Ray D, Farrow S, Singh D (2008) Inhibition of LPS stimulated COPD macrophage inflammatory gene expression by dexamethasone and the p38 MAPK inhibitor SB706504. J Pharmacol Exp Ther. doi:10.1124/jpet.108.142950
  217. 217.
    Loke TK, Mallett KH, Ratoff J, O’Connor BJ, Ying S, Meng Q, Soh C, Lee TH, Corrigan CJ (2006) Systemic glucocorticoid reduces bronchial mucosal activation of activator protein 1 components in glucocorticoid-sensitive but not glucocorticoid-resistant asthmatic patients. J Allergy Clin Immunol 118:368–375PubMedCrossRefGoogle Scholar
  218. 218.
    Cosio BG, Tsaprouni L, Ito K, Jazrawi E, Adcock IM, Barnes PJ (2004) Theophylline restores histone deacetylase activity and steroid responses in COPD macrophages. J Exp Med 200:689–695PubMedCrossRefGoogle Scholar
  219. 219.
    Ahmad T, Barnes PJ, Adcock IM (2008) Overcoming steroid insensitivity in smoking asthmatics. Curr Opin Investig Drugs 9:470–477PubMedGoogle Scholar
  220. 220.
    Rahman I, Adcock IM (2006) Oxidative stress and redox regulation of lung inflammation in COPD. Eur Respir J 28:219–242PubMedCrossRefGoogle Scholar
  221. 221.
    Rothschild BM (2008) Review: individual DMARDs have similar efficacy for RA, but combination therapy improves response. Evid Based Med 13:76PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • Kian Fan Chung
    • 1
  • Gaetano Caramori
    • 1
    • 2
  • Ian M. Adcock
    • 1
  1. 1.Airway Disease Section, National Heart and Lung InstituteImperial College LondonLondonUK
  2. 2.Department of Asthma and COPDUniversity of FerraraFerraraItaly

Personalised recommendations